{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:42:18Z","timestamp":1789245738480,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.04.031","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T12:07:29Z","timestamp":1626437249000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4310-4822","authenticated-orcid":false,"given":"Martin","family":"Salzmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Tosev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H.","family":"Enk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.ejca.2021.04.031_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2021.04.031_bib2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2021.04.031_bib3","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.031_bib4","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.2217\/fon-2019-0666","article-title":"KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma","volume":"16","author":"Luke","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2021.04.031_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Canc"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.031_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.031_bib7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/annonc\/mdw696","article-title":"Immune checkpoint inhibitors-related orchitis","volume":"28","author":"Brunet-Possenti","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.04.031_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1634\/theoncologist.2018-0722","article-title":"Severe epididymo-orchitis and encephalitis complicating anti-PD-1 therapy","volume":"24","author":"Quach","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2021.04.031_bib9","first-page":"101488","article-title":"Onset of azoospermia in man treated with ipilimumab\/nivolumab for BRAF negative metastatic melanoma","volume":"34","author":"Rabinowitz","year":"2021","journal-title":"Urol Case Rep"},{"issue":"8","key":"10.1016\/j.ejca.2021.04.031_bib10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaoncol.2020.1641","article-title":"Association of impaired spermatogenesis with the use of immune checkpoint inhibitors in patients with metastatic melanoma","volume":"6","author":"Scovell","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.031_bib11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaad.2016.04.031","article-title":"Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: fertility risk of Food and Drug Administration-approved systemic therapies","volume":"75","author":"Walter","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.ejca.2021.04.031_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11934-018-0803-2","article-title":"Male fertility preservation","volume":"19","author":"Abram McBride","year":"2018","journal-title":"Curr Urol Rep"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.031_bib13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.031_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/humupd\/dmp048","article-title":"World Health Organization reference values for human semen characteristics","volume":"16","author":"Cooper","year":"2010","journal-title":"Hum Reprod Update"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.031_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/humrep\/10.1.125","article-title":"Comparison of different methods for the investigation of antisperm antibodies on spermatozoa, in seminal plasma and in serum","volume":"10","author":"Andreou","year":"1995","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejca.2021.04.031_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2020.07.029","article-title":"Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study","volume":"138","author":"Salzmann","year":"2020","journal-title":"Eur J Canc"},{"issue":"4","key":"10.1016\/j.ejca.2021.04.031_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040957","article-title":"Effects of chemotherapy and radiotherapy on spermatogenesis: the role of testicular immunology","volume":"20","author":"Qu","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.031_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1439-0272.1987.tb01853.x","article-title":"Alcohol and male fertility (preliminary report)","volume":"19","author":"Brzek","year":"1987","journal-title":"Andrologia"},{"issue":"13","key":"10.1016\/j.ejca.2021.04.031_bib19","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2217\/imt-2017-0091","article-title":"Melanoma: a prototype of cancer-testis antigen-expressing malignancies","volume":"9","author":"Faramarzi","year":"2017","journal-title":"Immunotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2021.04.031_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.6061\/clinics\/2013(Sup01)03","article-title":"The epidemiology and etiology of azoospermia","volume":"68","author":"Cocuzza","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"issue":"34","key":"10.1016\/j.ejca.2021.04.031_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jncimonographs\/lgi003","article-title":"Spermatogenesis after cancer treatment: damage and recovery","author":"Howell","year":"2005","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.031_bib22","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.fertnstert.2013.08.010","article-title":"Effects of chemotherapy and radiotherapy on spermatogenesis in humans","volume":"100","author":"Meistrich","year":"2013","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.031_bib23","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/humupd\/dmw029","article-title":"Cryopreservation of testicular tissue or testicular cell suspensions: a pivotal step in fertility preservation","volume":"22","author":"Onofre","year":"2016","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejca.2021.04.031_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2020.03.016","article-title":"Adjuvant immunotherapy: the sting in the tail","volume":"132","author":"Higham","year":"2020","journal-title":"Eur J Canc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:16Z","timestamp":1760733076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492100277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":24,"alternative-id":["S095980492100277X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.031","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}